A study to investigate the triple combination of PTI-801, PTI-808 and PTI-428 in patients with cystic fibrosis

Trial Profile

A study to investigate the triple combination of PTI-801, PTI-808 and PTI-428 in patients with cystic fibrosis

Planning
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2018

At a glance

  • Drugs PTI 428 (Primary) ; PTI 808 (Primary) ; PTI-801 Proteostasis Therapeutics (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Proteostasis Therapeutics
  • Most Recent Events

    • 14 Mar 2018 According to a Proteostasis Therapeutics media release, dosing is expected to initiate in the second quarter of this year and preliminary clinical data expected in the second half of 2018.
    • 14 Mar 2018 According to a Proteostasis Therapeutics media release, the study protocol received endorsement and a high strategic fit score from the Therapeutics Development Network (TDN) and the Clinical Trial Network (CTN) in January 2018. This was based on the data from healthy volunteers and CF subjects, including proof-of-concept study with PTI-428 as add-on to Orkambi (see profile 261687)and healthy volunteer data from the coadministration study of all three of CFTR modulators (see profile 291295).
    • 10 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top